Atossa Therapeutics strikes sponsored research deal with Weill Cornell Medicine for triple negative breast cancerProactive Investors • 07/06/23
Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast CancerGlobeNewsWire • 07/06/23
Atossa Therapeutics hits 30% enrollment for (Z)-Endoxifen arm of ongoing I-SPY 2 clinical trialProactive Investors • 06/28/23
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical TrialPRNewsWire • 06/28/23
Pharmaceutical M&A thriving as global dealmaking struggles to stay healthyProactive Investors • 06/22/23
Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLCGlobeNewsWire • 06/14/23
Atossa Therapeutics is looking for a step-change in breast cancer therapyProactive Investors • 06/14/23
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast CancerGlobeNewsWire • 06/12/23
Atossa Therapeutics taps seasoned life sciences executive from its board to be CFOProactive Investors • 06/01/23
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial OfficerGlobeNewsWire • 06/01/23
Atossa Therapeutics breast cancer drug trial milestones and CAR-T M&A likely catalysts, analysts sayProactive Investors • 05/24/23
Atossa Therapeutics' 1Q results show ongoing breast cancer drug studies and robust cash on handProactive Investors • 05/15/23
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/23
Atossa Therapeutics CEO Steven Quay weighs in on US agency's revised mammogram guidelinesProactive Investors • 05/11/23
Physician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and PracticesPRNewsWire • 05/11/23
Atossa Therapeutics to present insights from ongoing EVANGELINE clinical trial at ASCO Annual MeetingProactive Investors • 05/09/23
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 05/09/23